BioSpace News Archive

Data from the clinical study showed that 40% of people treated with the Polivy regimen achieved a complete response.

“Over the past few years there has been a good amount of information presented at ADA. This year though, with all of the data presented, this was the most exciting year,” Todd Hobbs, U.S. chief medical officer of Novo Nordisk, told BioSpace in an exclusive interview.

Sugar.IQ Insights Viewed as Helpful and Enable Users to Avoid Diabetes-Related Events up to Four Hours in Advance

Pharming Group N.V. announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia.

The Dutch company Xenikos B.V. announced that the U.S. Food and Drug Administration has approved an investigational new drug application to initiate a U.S.-based clinical Phase 3 registration trial in order to test the efficacy of T-Guard for treating steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.

Spherix’s investment portfolio into emerging biotech stocks has resulted in substantial gains, turning a roughly $860,000 investment into a position worth more than $11 million at current share price levels, and marking a Price to Book ratio of less than 100%. The recently announced asset-purchase agreement of CBM BioPharma extends pipeline promise.

Aspera, the leading provider of solutions and services for Software Asset Management, announced the signing of a 3 year contract for delivery managed services to a enterprise that figures among the top 5 pharmaceutical companies in the world.

Medical device manufacturing remains a strong market, driven by technological developments, an aging population and increases in chronic and lifestyle diseases.

The approval was built on data from the Phase III KEYNOTE-048 clinical trial.

Denis Rebrikov indicates he plans to ask for approval from three government agencies, including Russia’s health ministry. He told Nature that could take anywhere from one month to two years.